Development of cell-based delivery systems that can release therapeutic levels of hematopoietic growth factors into the systemic circulation would facilitate treatment of patients requiring cytokine therapy. In this study, we have investigated the potential of granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting, irradiated syngeneic murine cells to accelerate hematopoietic recovery after cytotoxic chemotherapy. As a model, CMS-5 fibrosarcoma cells, were transduced with a retroviral vector containing the murine GM-CSF cDNA. Transduced cells secreted 38 ng GM-CSFI10' cells in 24 hours. After irradiation, in vitro GM-CSF production initially increased up to fivefold and was measurable for about 2 weeks. One and 2 days after injection of irradiated, GM-CSF-secreting CMS-5 cells (NPICMVGM-EMATOPOIETIC GROWTH factors have been shown to accelerate bone marrow (BM) recovery after chemotherapy and radiation therapy in mice."7 In humans, granulocyte colony-stimulating factor (G-CSF) and granulocytemacrophage colony-stimulating factor (GM-CSF) are widely used to shorten the phase of neutropenia after cytotoxic therapy and after BM transplantation.8"2 However, serum halflife of these cytokines is relatively short (eg, 35 minutes for GM-CSF after interperitoneal injection in mice) and continuous parenteral administration, eg, by the use of Alza miniosmotic pumps, or repetitive injections, has been used to maintain biologically effective serum concentrations.'"I5 Methods to provide sustained cytokine serum levels for several days without the need for daily injections or surgical implantation of delivery devices would be desirable. Autologous or allogeneic cells, genetically modified to constitutively secrete the cytokine of interest, could fulfill these criteria. Several investigators have already described the successful introduction of genes, coding for enzymes like al-antitrypsin or hormones like insulin, into murine fibroblasts or myoblasts, and the therapeutic application of these cells in animal deficiency models.'"z4 Other groups have introduced cytokine H
EMATOPOIETIC GROWTH factors have been shown
to accelerate bone marrow (BM) recovery after chemotherapy and radiation therapy in mice."7 In humans, granulocyte colony-stimulating factor (G-CSF) and granulocytemacrophage colony-stimulating factor (GM-CSF) are widely used to shorten the phase of neutropenia after cytotoxic therapy and after BM transplantation.8"2 However, serum halflife of these cytokines is relatively short (eg, 35 minutes for GM-CSF after interperitoneal injection in mice) and continuous parenteral administration, eg, by the use of Alza miniosmotic pumps, or repetitive injections, has been used to maintain biologically effective serum concentrations.'"I5 Methods to provide sustained cytokine serum levels for several days without the need for daily injections or surgical implantation of delivery devices would be desirable. Autologous or allogeneic cells, genetically modified to constitutively secrete the cytokine of interest, could fulfill these criteria. Several investigators have already described the successful introduction of genes, coding for enzymes like al-antitrypsin or hormones like insulin, into murine fibroblasts or myoblasts, and the therapeutic application of these cells in animal deficiency models.'"z4 Other groups have introduced cytokine genes into tumor cells to induce antitumor immune responses or into hematopoietic cells to study the controls modulating self-renewal and differentiation of hematopoietic ~e l l s .~~-~' Neutropenia after cytotoxic therapy is only transient, and thus, requires cytokine substitution for a limited time period only. Tani et alZ8 have designed a subcutaneous diffusion chamber apparatus for cytokine-producing fibroblasts that allows regulation of cytokine secretion either by reimplantation of additional cells into the chamber or by removing cells through ethanol treatment of the chamber. Ideally, gene expression would be regulated at the transcriptional level, eg, by the use of inducible promoters. Here we propose the use of irradiated cytokine-gene-transduced cells that have lost the capability to proliferate in vivo, but have retained the ability to secrete biologically active levels of cytokines for several days to weeks. Moreover, irradiation would be a precaution when cells are injected in vivo, as malignant transformation of genetically engineered fibroblasts has been described after in vivo implantation in mice."
In this report, we show acceleration of hematopoietic recovery after injection of irradiated GM-CSF-transduced murine fibrosarcoma cells in cyclophosphamide-treated mice.
infected cells were isolated by G41 8 selection, expanded to cell lines and used for further analysis.
Cyrokine assay. Secretion of GM-CSF into supernatants by retrovirally infected tumor cells and GM-CSF serum levels were determined using an appropriate bioassay and confirmed by enzymelinked immunosorbent assay (ELISA; Endogen, Boston, MA). Supernatant from semiconfluent irradiated or unirradiated parental or cytokine-secreting CMS-5 cells was collected after 24 hours, and assayed for GM-CSF production after determining the number of viable cells. Irradiation was performed at room temperature with a '37Cs-irradiation source at a dose-rate of 3 Gy/min. Irradiated (35, 50, and 100 Cy) CMS-5 and N2/CMVGM-CSF/CMS5 # 6 cells (lo6) were plated in 25-mL tissue-culture flasks and the amount of GM-CSF in a 24-hour culture supernatant l , 3,6,9, or 12 days after irradiation was determined. GM-CSF biologic activity was measured by testing the ability of GM-CSF-containing preparations to induce 'H-thymidine incorporation into DNA of GM-CSF-dependent murine 3 2 x 1 3 cells as previously de~cribed.2~
Treament of mice. Female BALB/c mice were purchased from the Zentralinstitut f i r Versuchstierzucht in Hannover, Germany and used at 9 to 11 weeks old. On day 0 and day 2, all mice received 150 mg/kg of cyclophosphamide interperitoneally. One group of mice did not receive further treatment, another group was injected subcutaneously with 100 ng of recombinant murine GM-CSF (rmGM-CSF; Boehringer Mannheim, Germany) twice daily on days 3 through 10. This dose of rmGM-CSF has previously been shown to accelerate hematopoietic recovery after chemotherapy in mice. ' The last group of mice was injected subcutaneously on day 3 with a total of lo7 irradiated N2lCMVGM-CSFlCMS5 # 6 cells, split into two injection sites. From day 4, blood was drawn daily from lateral tail veins into EDTA-coated microvette tubes (Sarstedt, Heidelberg, Germany). After lysis of erythrocytes with Turk solution, absolute leukocyte counts were determined in a Neubauer Chamber. Differential counts were performed every other day. GM-CSF serum levels were determined on days 1 through 4 after injection of GM-CSFproducing cells.
Statistical analyses. Mean ? SE was calculated. Differences between groups were examined for statistical significance by a twotailed, two-sample t-test. A P value s .05 was considered to indicate statistical significance.
RESULTS

Infection ofjibrosarcoma cells.
The structures of the retroviral vectors used to transduce the murine fibrosarcoma cell line CMS-5 have been described previou~ly?~ Viruscontaining, cell-free supernatant of infected packaging cell clones was used to transduce CMS-5 cells. G418-resistant CMS-5 bulk-infected cells were screened for GM-CSF expression by analyzing GM-CSF release into the culture supernatant. Parental CMS-5 cells did not secrete any detectable GM-CSF in either assay. G418-resistant cytokine gene transduced cells differed in their ability to synthesize and secrete GM-CSF, depending on the retroviral vector construct and the virus-producer clone used to transduce target cells (Table 1) . GM-CSF secretion of bulk-infected fibrosarcoma cells transduced with the GM-CSF vector ranged from 0 to 128 ng/106 cells in 24 hours. GM-CSF production of cells was found to decrease after extended periods of culture without G418 selection. Bulk-infected NUCMVGM-CSF/CMSS # 6 cells that were used for the in vivo studies described here, secreted 38 ng/106 cells in 24 hours unless irradiated (see below). GM-CSF secretion after irradiation of cytokine-genetransduced jibrosarcoma cells. To prevent proliferation of cytokine producing cells in vivo, cells were irradiated before injection. To study how long cytokine secretion would continue after irradiation, N2/CMVGM-CSF/CMS5 # 6 cells were irradiated with 35, 50, and 100 Gy, respectively, and plated at a density of lo6 cells/25-mL tissue-culture medium.
GM-CSF levels in 24-hour culture supernatants were determined 1, 3, 6, 9, and 12 days after irradiation. Unirradiated N2/CMVGM-CSF/CMS5 # 6 cells produced 38 ng/106 cells in 24 hours (Fig 1, day -1 before irradiation). After irradiation, cytokine secretion initially increased threefold to fivefold depending on the dose of irradiation applied. GM-CSF levels decreased to levels similar to those observed before irradiation by day 12. As the number of viable cells decreased continuously, these data suggest that biologically active GM-CSF is also released by radiation-damaged cells for several days.
GM-CSF serum levels after injection of GM-CSF-secretingjibrosarcoma cells in BALB/c mice. To obtain information about the time course of GM-CSF serum concentrations, blood was drawn at different time points after subcutaneous injection of irradiated N2/CMVGM-CSF/CMS5 # 6 cells or 3 and 10 hours after subcutaneous injection of rmGM-CSF. GM-CSF serum levels were determined in a bioassay and confirmed by ELISA. In Fig 2A, GM-CSF serum levels of mice injected subcutaneously with 100 ng rmGM-CSF are shown 3 and 10 hours after injection. Three hours after injection of rmGM-CSF, a serum level of 93 t 1 1 pg/mL was measured, whereas at 10 hours, serum GM-CSF levels were below the limit of detection. Figure 2B shows GM-CSF serum levels 1 to 4 days after injection of lo7 irradiated N2/ CMVGM-CSFfCMS5 # 6 cells, which is 3 to 6 days after initiation of cytotoxic therapy. One and 2 days after injection of GM-CSF-secreting cells, GM-CSF serum levels of 405 t 58 pg/mL and 183 2 36 pg/mL were measured, respectively. On days 3 and 4, GM-CSF serum levels were 88 2 24 pg/mL and 82 t 26 pg/mL, respectively, comparable with the level detected 3 hours after subcutaneous injection of 100 ng rmGM-CSF. No GM-CSF was found in the serum of mice injected with the same number of parental, nontransduced CMS-5 cells.
Hematologic changes in cyclophosphamide-treated mice, after injection of GM-CSF-secreting fibrosarcoma cells or twice daily injections of recombinant GM-CSF. Nine-to 1 l-week-old female BALB/c mice were injected intraperito- neally on days 0 and 2 with l50 mgkg cyclophosphamide, BALB/c mice were between 9,000 and lO,OOO/pL. Three the control group did not receive further treatment. One days after initiation of cyclophosphamide therapy leukocyte group of mice was injected subcutaneously with IO' irradicounts dropped to nadir levels of 1,000 to 1,5OO/yL in all ated N2/CMVGM-CSF/CMSS # 6 cells on day 3, another mice, persisting until day 6. Starting from day 7, a difference group was injected twice daily (d3-d10) subcutaneously with in absolute leukocyte counts between GM-CSF-treated mice 100 ng of rmCM-CSF. For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From in mice injected subcutaneously twice daily with rmGM-CSF as well as in mice treated with a single injection of irradiated GM-CSF-secreting syngeneic cells were significantly higher as compared with control mice (cyclophosphamide v GM-CSF subcutaneously: P = .010, cyclophosphamide v NUCMVGM-CSFICMSS #6: P = .036). Average WBC counts on day 7 were 4,38O/pL in the cytokine treatment group compared with 3,005/pL in control mice. On day 8,WBC count of the cytokine treatment group had increased to 9,26O/pL, and in controls to 6,34O/pL. In mice treated with rmGM-CSF subcutaneously or with GM-CSFsecreting cells, leukocyte counts continued to increase until day 9 and returned toward baseline levels on day 10. After recovery of hematopoiesis (eg, after day 9) no siginficant difference in absolute leukocyte counts is e~pected.~ Table 2 shows differential W C counts of treatment groups as absolute values of leukocyte subpopulations on days 7 and 8 after initiation of treatment. Untreated BALB/ c mice had a differential count of about 400 monocytes, 1,800 granulocytes and 7,100 lymphocytes. On day 3 through 5, ie, 1 to 3 days after cytotoxic therapy, blood smear examinations showed absolute neutropenia (< 100/ pL) in all treatment groups (data not shown). On day 7, mice treated with subcutaneous rmGM-CSF or GM-CSFsecreting cells showed almost twice the absolute leukocyte levels of control mice, accounted for by a higher proportion of myeloid cells. Baseline myeloid counts were reached in both GM-CSF-treated populations 7 days after the first cyclophosphamide injection or 4 days after initiation of cytokine treatment, respectively, whereas control mice had only reached approximately half-normal values at that time. No significant differences in absolute lymphocyte counts were noted between different treatment groups. On day 8, the difference in absolute myeloid cells between cyclophosphamideonly-treated mice and those with addition of hematopoietic growth factor treatment was even more pronounced (cyclophosphamide v GM-CSF subcutaneously: P = .019, cyclophosphamide v NUCMVGM-CSFICMS5 M: P = .W).
DISCUSSION
The use of recombinant hematopoietic growth factors has reduced morbidity of cytotoxic chemotherapy in tumor pa- tients by amelioration of neutropenia and its associated infectious complications.8"2 Currently, growth factors are applied by daily subcutaneous injections or continuous intravenous infusion. In this study, we show that a single injection of irradiated GM-CSF-transduced murine fibrosarcoma cells is as effective in accelerating hematopoietic recovery after cyclophosphamide chemotherapy as twice daily subcutaneous injections of recombinant GM-CSF.
Because long-term expression of GM-CSF is not desirable for the treatment of chemotherapy-induced neutropenia, nonproliferating cells with a finite life span should be used. Irradiation of transfected cells is one option and has the additional advantage of preventing outgrowth of possibly transformed cells in vivo. 28 Here we show that after irradiation of GM-CSF gene-transduced cells with up to 100 Gy, cytokine production persisted for more than 12 days in vitro (Fig 1) . After irradiation, GM-CSF secretion initially increased. This effect could possibly be caused by cytokine leakage from radiation-damaged cells or by radiation-induced activation of transcription factors.'*,'' Irradiated cells were incapable of further proliferation in vitro, as shown by decreasing cell numbers over time. There was no evidence of tumor growth or other side effects in mice observed for up to 2 months after treatment (data not shown).
After injection of lo7 irradiated GM-CSF-secreting syngeneic cells, circulating GM-CSF was measurable for 4 days, reaching peak levels of 405 ? 58 pg/mL on the first day after injection and decreasing slowly thereafter (Fig 2) . GM-CSF serum level 3 hours after subcutaneous injection of 100 ng rmGM-CSF was 93 2 11 pg/mL, comparable with that found 3 and 4 days after injection of irradiated GM-CSFsecreting cells. Ten hours after subcutaneous injection, GM-CSF was no longer detectable in serum. These data show that after injection of cells that continuously secrete GM-CSF, sustained serum levels are achieved as opposed to only transient elevation found after subcutaneous injection.
Accelerated recovery of WBCs and total myeloid cells after twice daily subcutaneous GM-CSF treatment after cyclophosphamide therapy has been previously shown by Gamba-Vitalo et al. 3 Here we confirm the effects of twice daily subcutaneous rmGM-CSF injections on WBC and myeloid recovery and show that injection of irradiated GM-CSF-secreting syngeneic cells is at least as efficacious (Fig  3 and Table 2 ). Although implanted devices as described by Tani et alZ8 or miniosmotic pumps are likely to be equally effective, both approaches require surgical interventions.l4,l5
With current technology, it is unlikely that cytokine-genetransfected cells would replace administration of recombinant growth factors in transient, chemotherapy-induced neutropenias except in special circumstances when poor patient compliance or other factors make daily administration difficult or impossible. However, successful treatment of chronic neutropenic disorders like Kostmann's syndrome (congenital neutropenia) and cyclic or idiopathic neutropenias with genetically engineered cells or slow-release formulations of G-CSF might be possible in the near fut~re.'~.'' In this situation, the application of G-CSF gene-transfected unirradiated, nonproliferating autologous cells, possibly in conjunction with a suicide gene allowing interruption of cytokine secretion in case of detrimental effects or other clinical indications, appears to be a promising strategy, and is currently under investigation in our laboratory.zz~23~36 
